<DOC>
	<DOCNO>NCT01980472</DOCNO>
	<brief_summary>A phase II Study adapt chemotherapy regimen plus bevacizumab elderly non-small cell lung cancer patient select geriatric assessment</brief_summary>
	<brief_title>Chemotherapy Plus Bevacizumab Elderly Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description>CRITERIOS INCLUSION - Written inform consent confirm patient understands study objective procedure require . - Patients must able accomplish study protocol . - Men woman ≥70 year old . - Histologically cytologically confirm diagnosis non-squamous non-small cell lung cancer ( NSCLC ) EGFR gen mutational status negative non-determinable . - Patients stage IV disease . - Patients receive first-line treatment - Patients ECOG performance status 0 1 . - Adequate bone marrow function , define : - Absolute neutrophil count ( ANC ) ≥1.500/mm3 ≥1.5x109/L ; - Hemoglobin ≥ 9 g/dL . - Platelet count ≥ 100.000/mm3 . - Adequate renal function , define : - Creatinine clearance ≥ 40 ml/min , accord MDRD formula . - Urine dipstick proteinuria &lt; 2+ . If urine dipstick proteinuria ≥2+ 24 hour urine must collect within 24 hour , protein must less 1 g. - Fertile male must use effective contraceptive method ( error rate per year &lt; 1 % ) trial 6 month last study treatment dose , sexual abstinence , previous vasectomy and/or partner use follow method : implantables , injection , combine oral contraceptive and/or intrauterine device ( hormonal ) . CRITERIOS EXCLUSION - Previous chemotherapy advance NSCLC . - History haemoptysis grade ≥ 2 ( define least 2.5 mL bright red blood ) 3 month inclusion . - Major surgery ( include open biopsy ) , significant traumatic injury 28 day inclusion anticipation need major surgical procedure treatment period - Minor surgery , include permanent catheter insertion , 24 hour bevacizumab infusion . - Untreated brain metastasis . Patients CNS metastasis treat radiotherapy surgery may include evidence progression treatment - Radiological evidence tumor invades adjacent main blood vessel ( e.g . lung artery superior cava venous ) . - Radiotherapy , lesion reason , within 28 day inclusion . Palliative radiotherapy bone lesion within 14 day inclusion allow . - Treatment aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg/day ) within 10 day prior bevacizumab first dose . Use full dose oral parenteral anticoagulant thrombolytic agent therapeutic dos . Prophylactic use anticoagulant therapy allow . - Uncontrolled hypertension ( systolic BP &gt; 140 mmHg , diastolic BP &gt; 90mmHg ) 28 day previous inclusion history hypertensive crisis , hypertensive encephalopathy . - Clinically significant cardiovascular disease ( i.e . cerebrovascular accident ( CVA ) , myocardial infarction within 6 month prior inclusion , unstable angina , congestive cardiac insufficiency NYHA ≥ II , leave ventricular ejection fraction ( LVEF ) &lt; 50 % serious cardiac arrhytmia ) , respond treatment interfere trial treatment administration . - Not heal wound , active peptic ulcer untreated bone fracture . - Hypersensibility active ingredient study treatment ( bevacizumab , carboplatine paclitaxel ) excipients . - Serious cognitive impairment limit patient understand answer study questionnaire . - Inability comply study protocol and/or follow-up procedure due psychological , familiar , social geographical problem - Patients ADL score &lt; 5 screening . - Patients dementia : 9-12 point Folstein MMS screening . - Patients accomplish fragility Balducci criterion screen : - Age ≥ 85 year old - Dependence 1 ADL - &gt; 3 comorbilities - &gt; 1 geriatric syndrome OBJETIVOS To assess toxicity treatment elderly patient ( ≥70 year ) NSC lung cancer meet inclusion criterion bevacizumab select base geriatric evaluation . Determine predictive factor toxicity elderly population ( ≥70 year ) . Determine objective response rate Determine disease control rate Determine progression free survival Determine overall survival Determine safety treatment combination VARIABLES Primary endpoint : Rate grade 3-4 neutropenia define accord National Cancer Institute Common Terminology Criteria version 4.0 ( NCI-CTC v4.0 ) . Secondary endpoint : - Items Comprehensive Geriatric Assessment ( CGA ) scale predictive factor toxicity end-points . - Objective response accord Response Evaluation Criteria In Solid Tumors ( RECIST v1.1 ) . - Progression-free survival . - Overall survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Written inform consent confirm patient understands study objective procedure require . Patients must able accomplish study protocol . Men woman ≥70 year old . Histologically cytologically confirm diagnosis nonsquamous nonsmall cell lung cancer ( NSCLC ) EGFR gen mutational status negative nondeterminable . Patients stage IV disease . Patients receive firstline treatment Patients ECOG performance status 0 1 . Adequate bone marrow function , define : Absolute neutrophil count ( ANC ) ≥1.500/mm3 ≥1.5x109/L ; Hemoglobin ≥ 9 g/dL . Platelet count ≥ 100.000/mm3 . • Adequate renal function , define : Creatinine clearance ≥ 40 ml/min , accord MDRD formula . Urine dipstick proteinuria &lt; 2+ . If urine dipstick proteinuria ≥2+ 24 hour urine must collect within 24 hour , protein must less 1 g. • Fertile male must use effective contraceptive method ( error rate per year &lt; 1 % ) trial 6 month last study treatment dose , sexual abstinence , previous vasectomy and/or partner use follow method : implantables , injection , combine oral contraceptive and/or intrauterine device ( hormonal ) . Previous chemotherapy advance NSCLC . History haemoptysis grade ≥ 2 ( define least 2.5 mL bright red blood ) 3 month inclusion . Major surgery ( include open biopsy ) , significant traumatic injury 28 day inclusion anticipation need major surgical procedure treatment period Minor surgery , include permanent catheter insertion , 24 hour bevacizumab infusion . Untreated brain metastasis . Patients CNS metastasis treat radiotherapy surgery may include evidence progression treatment Radiological evidence tumor invades adjacent main blood vessel ( e.g . lung artery superior cava venous ) . Radiotherapy , lesion reason , within 28 day inclusion . Palliative radiotherapy bone lesion within 14 day inclusion allow . Treatment aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg/day ) within 10 day prior bevacizumab first dose . Use full dose oral parenteral anticoagulant thrombolytic agent therapeutic dos . Prophylactic use anticoagulant therapy allow . Uncontrolled hypertension ( systolic BP &gt; 140 mmHg , diastolic BP &gt; 90mmHg ) 28 day previous inclusion history hypertensive crisis , hypertensive encephalopathy . Clinically significant cardiovascular disease ( i.e . cerebrovascular accident ( CVA ) , myocardial infarction within 6 month prior inclusion , unstable angina , congestive cardiac insufficiency NYHA ≥ II , leave ventricular ejection fraction ( LVEF ) &lt; 50 % serious cardiac arrhythmia ) , respond treatment interfere trial treatment administration . Not heal wound , active peptic ulcer untreated bone fracture . Hypersensibility active ingredient study treatment ( bevacizumab , carboplatine paclitaxel ) excipients . Serious cognitive impairment limit patient understand answer study questionnaire . Inability comply study protocol and/or followup procedure due psychological , familiar , social geographical problem Patients ADL score &lt; 5 screening . Patients dementia : 912 point Folstein MMS screen . Patients accomplish fragility Balducci criterion screen : Age ≥ 85 year old Dependence 1 ADL &gt; 3 comorbidities &gt; 1 geriatric syndrome</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>